64Cu-labeled anti-EphB4 antibodies (USC/VasGene Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name64Cu-labeled anti-EphB4 antibodies (USC/VasGene Therapeutics)
Drug Alias NameN/A
ClassificationRadiation-emitting productsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionEphrin type-B receptor 4 antagonists78 kDa glucose-regulated protein inhibitors
Targets78 kDa glucose-regulated proteinEphrin type-B receptor 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVasgene Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Southern CaliforniaVasgene Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A